First Patients in the UK Receive Doses of Blue Earth Therapeutics' Investigational Radiopharmaceutical Therapy Lutetium (177Lu) rhPSMA-10.1 Injection for Metastatic Castrate Resistant Prostate Cancer ...Middle East

St Bartholomew's Hospital and The James Cook University Hospital mark key UK expansion of the company's Phase 2 mCRPC programme The patients received Lutetium (177Lu) rhPSMA-10.1 Injections at both St Bartholomew's Hospital, London, and The James Cook University Hospital, Middlesbrough...

Hence then, the article about first patients in the uk receive doses of blue earth therapeutics investigational radiopharmaceutical therapy lutetium 177lu rhpsma 10 1 injection for metastatic castrate resistant prostate cancer was published today ( Thursday 15/01/2026 - 02:02 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( First Patients in the UK Receive Doses of Blue Earth Therapeutics' Investigational Radiopharmaceutical Therapy Lutetium (177Lu) rhPSMA-10.1 Injection for Metastatic Castrate Resistant Prostate Cancer )

Also on site :

• Who Is High Voltage on ‘The Masked Singer’? The Electric Clues Point One Way
• Mira Murati’s startup, Thinking Machines Lab, is losing two of its co-founders to OpenAI
• Gaza plan phase two: US to discuss Hamas disarmament, Israeli withdrawal